{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:50:45Z","timestamp":1794318645971,"version":"4.9.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ebiom.2025.105862","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:17:31Z","timestamp":1753298251000},"page":"105862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats"],"prefix":"10.1016","volume":"118","author":[{"given":"Rune Ehrenreich","family":"Kuhre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ballar\u00edn-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Lehn","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Glendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Grimstrup","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Rahr","family":"Hj\u00f8llund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-5325","authenticated-orcid":false,"given":"Wouter Frederik Johan","family":"Hogendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H\u00f8jland","family":"Ipsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Lundh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe Beck","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Secher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Vegge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7605-8215","authenticated-orcid":false,"given":"Kirsten","family":"Raun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.105862_bib2","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications","volume":"13","author":"Wondmkun","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"10397","key":"10.1016\/j.ebiom.2025.105862_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105862_bib4","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105862_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.21037\/atm.2017.03.107","article-title":"Morbidity and mortality associated with obesity","volume":"5","author":"Abdelaal","year":"2017","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105862_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101182","article-title":"Insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD): pathways of action of hypoglycemic agents","volume":"29","author":"Maldonado-Rojas","year":"2024","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105862_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2025.105862_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105862_bib9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105862_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105862_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"issue":"15","key":"10.1016\/j.ebiom.2025.105862_bib12","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105862_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"467","key":"10.1016\/j.ebiom.2025.105862_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105862_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/db18-0729","article-title":"Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food","volume":"68","author":"Holt","year":"2019","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105862_bib16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.ebiom.2025.105862_bib17","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/ijo.2009.13","article-title":"Control of food intake and energy expenditure by amylin\u2014therapeutic implications","volume":"33","author":"Lutz","year":"2009","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105862_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031517","article-title":"Amylin, another important neuroendocrine hormone for the treatment of diabesity","volume":"25","author":"Er\u017een","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6587","key":"10.1016\/j.ebiom.2025.105862_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"issue":"10317","key":"10.1016\/j.ebiom.2025.105862_bib20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.ebiom.2025.105862_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105862_bib22","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"issue":"10286","key":"10.1016\/j.ebiom.2025.105862_bib23","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ebiom.2025.105862_bib26","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.ebiom.2025.105862_bib27","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105862_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246569","article-title":"The feeding microstructure of male and female mice","volume":"16","author":"Rathod","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105862_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nmeth.1806","article-title":"A guide to analysis of mouse energy metabolism","volume":"9","author":"Tsch\u00f6p","year":"2011","journal-title":"Nat Methods"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105862_bib30","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1021\/jo011148j","article-title":"Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides","volume":"67","author":"Torn\u00f8e","year":"2002","journal-title":"J Org Chem"},{"key":"10.1016\/j.ebiom.2025.105862_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109637","article-title":"Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging","volume":"238","author":"Skovbjerg","year":"2023","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105862_bib32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12021-020-09490-8","article-title":"An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy","volume":"19","author":"Perens","year":"2021","journal-title":"Neuroinformatics"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105862_bib33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1109\/TMI.2009.2035616","article-title":"elastix: A toolbox for intensity-based medical image registration","volume":"29","author":"Klein","year":"2010","journal-title":"IEEE Trans Med Imaging"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105862_bib34","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105862_bib35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nat Metab"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105862_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105862_bib37","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"S1","key":"10.1016\/j.ebiom.2025.105862_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/oby.23626","article-title":"Poster abstracts","volume":"30","author":"Secher","year":"2022","journal-title":"Obesity"},{"issue":"S1","key":"10.1016\/j.ebiom.2025.105862_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/oby.24195","article-title":"Poster abstracts","volume":"32","author":"Lundh","year":"2024","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105862_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105862_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078154","article-title":"Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids","volume":"8","author":"Trevaskis","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105862_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsptsci.8b00002","article-title":"Molecular signature for receptor engagement in the metabolic peptide hormone amylin","volume":"1","author":"Bower","year":"2018","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105862_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/oby.20027","article-title":"Adaptive thermogenesis with weight loss in humans","volume":"21","author":"M\u00fcller","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105862_bib44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13679-016-0237-4","article-title":"Changes in energy expenditure with weight gain and weight loss in humans","volume":"5","author":"M\u00fcller","year":"2016","journal-title":"Curr Obes Rep"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105862_bib45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jama.1935.02760310006002","article-title":"Dinitrophenol in the treatment of obesity: final report","volume":"105","author":"Tainter","year":"1935","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105862_bib46","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/jnc.13176","article-title":"The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation","volume":"134","author":"Liu","year":"2015","journal-title":"J Neurochem"},{"key":"10.1016\/j.ebiom.2025.105862_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102027","article-title":"Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice","volume":"89","author":"Petersen","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.ebiom.2025.105862_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-025-01324-8","article-title":"CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure","author":"Jacobsen","year":"2025","journal-title":"Nat Metab"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105862_bib49","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105862_bib50","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"10499","key":"10.1016\/j.ebiom.2025.105862_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class, dual-acting amylin and GLP-1 receptor agonist, amycretin: a first-in-human phase 1 randomised, placebo-controlled study","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"issue":"10499","key":"10.1016\/j.ebiom.2025.105862_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist for subcutaneous administration: results of a randomised, controlled, phase 1b\/2a study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ebiom.2025.105862_bib53","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105862_bib54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/biomedicines12030657","article-title":"Transforming diabetes care: the molecular pathways through which GLP1-RAs impact the kidneys in diabetic kidney disease","volume":"12","author":"Rroji","year":"2024","journal-title":"Biomedicines"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:51:12Z","timestamp":1772761872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425003068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"alternative-id":["S2352396425003068"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105862","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105862"}}